Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) EBIT (2023 - 2025)

Historic EBIT for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$2.2 million.

  • BioLineRx's EBIT rose 5903.1% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.3 million, marking a year-over-year increase of 6721.37%. This contributed to the annual value of -$20.4 million for FY2024, which is 5893.27% up from last year.
  • Per BioLineRx's latest filing, its EBIT stood at -$2.2 million for Q3 2025, which was up 5903.1% from -$2.3 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's EBIT registered a high of -$2.2 million during Q3 2025, and its lowest value of -$18.6 million during Q4 2023.
  • Its 3-year average for EBIT is -$7.0 million, with a median of -$5.4 million in 2024.
  • Over the last 5 years, BioLineRx's EBIT had its largest YoY gain of 7616.07% in 2024, and its largest YoY loss of 4177.51% in 2024.
  • Over the past 3 years, BioLineRx's EBIT (Quarter) stood at -$18.6 million in 2023, then surged by 76.16% to -$4.4 million in 2024, then soared by 50.14% to -$2.2 million in 2025.
  • Its EBIT was -$2.2 million in Q3 2025, compared to -$2.3 million in Q2 2025 and -$2.4 million in Q1 2025.